당뇨병성 위마비 치료 시장 : 제품 유형별, 적응증별, 유통 채널별 및 지역별

Diabetic Gastroparesis Treatment Market is estimated to be valued at USD 2,531.2 Mn in 2026 and is expected to reach USD 3,286.3 Mn by 2033, growing at a compound annual growth rate (CAGR) of 3.8% from 2026 to 2033.

Gastroparesis is the delaying of gastric emptying without any evidence of mechanical obstruction. Diabetic gastroparesis is a potential complication that occurs in the setting of poorly controlled diabetes, resulting from dysfunction in the coordination and function of the autonomic nervous system, neurons, and specialized pacemaker cells of the stomach and intestine, and the smooth muscle cells of the gastrointestinal tract. Diabetic gastroparesis occurs as a result of dysfunction in the autonomic and enteric nervous systems. Chronically high levels of blood glucose (or inefficient glucose uptake) lead to neuronal damage resulting in abnormal myenteric neurotransmission, impaired inhibitory neuronal function, and dysfunctional smooth muscle and pacemaker cells of stomach.

Altogether, this dysfunction results in a combination of fewer contractions of the antrum, uncoordinated antro-duodenal contractions, and pyloric spasms, ultimately resulting in delayed gastric emptying (gastroparesis). Delayed gastric emptying in patients with diabetes, particularly of solids, may also occur in the setting of abnormal small bowel motility, which is thought to occur by a similar mechanism as that which is described in the stomach. Some patients with diabetes may additionally experience changes in gastric compliance, both increased or decreased, which may also contribute to delayed gastric emptying.

Market Dynamics

Increasing prevalence of diabetes worldwide, increasing geriatric population and sedentary lifestyle, increasing affordability and accessibility of medication to patients, and research and development activities on diabetic gastroparesis attributed to the growth of global diabetic gastroparesis treatment market. For instance, on June 23, 2020, Evoke Pharma, a U.S.-based pharmaceutical company, announced that the U.S. Food And Drug Administration has approved the new drug application for Gimoti nasal spray to relieve symptoms in adults with acute and recurrent diabetic gastroparesis. The drug, Metoclopramide has limited use due to associated side effects. Hence, a novel approach by introducing drug in trans nasal pathway is taken.

Key features of the study:

• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global diabetic gastroparesis market based on the following parameters-Company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Janssen Global Services, LLC, Cardinal Health, Inc., Evoke Pharma, Inc., Salix Pharmaceuticals, Inc., Alfa Wassermann SPA, Abbott Laboratories, Medtronic Plc., C. R. Bard, Inc. (Becton, Dickinson and Company), Rhythm Pharmaceuticals, Inc., Boston Scientific Corporation, Kimberly-Clark Corporation, Vanda Pharmaceuticals, Inc., and Allergan, plc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global diabetic gastroparesis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global diabetic gastroparesis treatment market

Detailed Segmentation:

• Global Diabetic Gastroparesis Treatment Market, By Product Type (Revenue, USD Mn, 2021 - 2033)
• Drugs
  • Gastroprokinetic Agents
  • Antiemetic Agents
  • Botulinum Toxin
• Surgical Treatment Products
  • Gastric Electrical Stimulation (GES) Device
  • Percutaneous Endoscopic Gastrostomy (PEG) Kit
  • Parenteral Nutrition
• Global Diabetic Gastroparesis Treatment Market, By Disease Indication (Revenue, USD Mn, 2021 - 2033)
• Compensated Gastroparesis
• Gastric Failure
• Global Diabetic Gastroparesis Treatment Market, By Distribution channel (Revenue, USD Mn, 2021 - 2033)
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Global Diabetic Gastroparesis Treatment Market, By Region (Revenue, USD Mn, 2021 - 2033)
• North America
  • U.S.
  • Canada
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • GCC
  • Israel
  • Rest of Middle East
• Africa
  • South Africa
  • Central Africa
  • North Africa
• Company Profiles
• Janssen Global Services
• LLC, Cardinal Health, Inc.
• Evoke Pharma, Inc.
• Salix Pharmaceuticals, Inc.
• Alfa Wassermann SPA
• Abbott Laboratories
• Medtronic Plc.,
• C.R. Bard, Inc. (Becton, Dickinson and Company)
• Rhythm Pharmaceuticals, Inc.
• Boston Scientific Corporation
• Kimberly-Clark Corporation
• Vanda Pharmaceuticals, Inc.
• Allergan, plc.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Product Type
  • Market Snapshot, By Disease Indication
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Drivers
• Restraints
• Market Opportunities
• Impact Analysis
• Recent Product Launches
• Epidemiology
• Merger, Acquisition, and Collaborations
• Regulatory Scenario
• Key Developments
• PEST Analysis

4. Global Diabetic Gastroparesis Treatment Market, By Product Type, 2021 - 2033, (US$ Million)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022-2033
  • Segment Trends
• Drugs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
  • Segment Trends
    • Gastroprokinetic Agents
    • Antiemetic Agents
    • Botulinum Toxin
• Surgical Treatment Products
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
  • Segment trends
    • Gastric Electrical Stimulation (GES) Device
    • Percutaneous Endoscopic Gastrostomy (PEG) Kit
    • Parenteral Nutrition

5. Global Diabetic Gastroparesis Treatment Market, By Disease Indication, 2021 - 2033, (US$ Million)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022-2033
  • Segment Trends
• Compensated Gastroparesis
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
• Gastric Failure
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)

6. Global Diabetic Gastroparesis Treatment Market, By Distribution channel, 2021 - 2033, (US$ Million)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022-2033
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)

7. Global Diabetic Gastroparesis Treatment Market, By Region, 2021 - 2033, (US$ Million)

• Introduction
  • Market Share Analysis, By Region, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, For Regions, 2022-2033
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product type, 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication , 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel , 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product type, 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication , 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel , 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021- 2033, (US$ Million)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product type, 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication , 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel , 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021- 2033, (US$ Million)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product type, 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication , 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel , 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021- 2033, (US$ Million)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product type, 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication , 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel , 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021- 2033, (US$ Million)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product type, 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication , 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel , 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021- 2033, (US$ Million)
    • North Africa
    • Central Africa
    • South Africa

8. Competitive Landscape

• Janssen Global Services, LLC
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Cardinal Health, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Evoke Pharma, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Salix Pharmaceuticals, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Alfa Wassermann SPA
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Abbott Laboratories
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Medtronic Plc
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• C.R. Bard, Inc. (Becton, Dickinson and Company)
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Rhythm Pharmaceuticals, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Boston Scientific Corporation
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Kimberly-Clark Corporation.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Vanda Pharmaceuticals, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Allergan, plc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies

9. Section

• Research Methodology
• About Us